Clinical Trial Update: Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19 [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for Treamid in patients with reduced exercise tolerance after COVID-19, spanning Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Fibrosis

Drugs mentioned

• Treamid

Snippet

Sponsor: PHARMENTERPRISES LLC | Conditions: SARS-CoV-2 Infection, Lung Fibrosis | Phase 2, Phase 3 | Status: UNKNOWN